# US 2019/0316102 A1 · Modification of immune-related genomic loci using paired crispr nickase ribonucleoproteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316102 A1
- Document ID: US20190316102A1
- Status: Published application
- Kind: A1
- Application number: 16/383,135
- Filed: 2019-04-12
- Published: 2019-10-17
- Earliest claimed: 2018-04-13
- Assignees: Sigma-Aldrich Co.
- Applicants: Sigma-Aldrich Co. LLC
- Inventors: Qingzhou Ji; Gregory D. Davis; Jacob T. Lamberth
- Web page: https://patentgrep.com/patent/US20190316102A1

## CPC

- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- C12N 5/0636: {T lymphocytes}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/907: {in mammalian cells}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Paired CRISPR nickase ribonucleoproteins engineered to target immune-related genomic loci and methods of using said ribonucleoproteins to modify the immune-related genomic loci.

## Claims

### Claim 1

A method for modifying an immune-related genomic locus in a eukaryotic cell, the method comprising introducing into the eukaryotic cell Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) nickase ribonucleoproteins (RNPs) comprising a pair of guide RNAs designed to hybridize with target sequences in the immune-related genomic locus, such that repair of a double-stranded break created by the CRISPR nickase RNPs results in modification of the immune-related genomic locus.

### Claim 2 (depends on 1)

The method of claim 1, wherein the target sequences of the pair of guide RNAs are on opposite strands of the immune-related genomic locus.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pair of guide RNAs is configured such that each protospacer adjacent motif (PAM) sequence adjacent to one of the target sequences is facing outwards (or is located at a distal end of the target sequences).

### Claim 4 (depends on 3)

The method of claim 3, where the distance between the PAM sequences is from about 35 base pairs to about 120 base pairs.

### Claim 5 (depends on 1)

The method of claim 1, wherein the CRISPR nickase RNP comprises a Cas9 nickase, a Cpf1 nickase, or a Cas13a nickase.

### Claim 6 (depends on 5)

The method of claim 5, wherein the CRISPR nickase RNP comprises a Cas9 nickase.

### Claim 7 (depends on 6)

The method of claim 6, wherein the Cas9 nickase is a SpCas9 nickase, a FnCas9 nickase, or a SaCas9 nickase.

### Claim 8 (depends on 7)

The method of claim 7, wherein the Cas9 nickase is a Cas9-D10A nickase or a Cas9-H840A nickase.

### Claim 9 (depends on 1)

The method of claim 1, wherein the CRISPR nickase comprises at least one nuclear localization signal, at least one cell-penetrating domain, at least one marker domain, at least one chromatin disrupting domain, or a combination thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the molar ratio of the pair of guide RNAs to CRISPR nickase is 0.5:1, 1:1, 1.5:1, 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, 5:1, 5.5:1, 6:1, 6.5:1, 7:1, 7.5:1, 8:1, 8.5:1, 9:1, 9.5:1, or 10:1.

### Claim 11 (depends on 1)

The method of claim 1, wherein the eukaryotic cell is a human cell or a non-human mammalian cell.

### Claim 12 (depends on 11)

The method of claim 11, wherein the eukaryotic cell is a primary T cell.

### Claim 13 (depends on 1)

The method of claim 1, wherein the pair of guide RNAs is chosen from (a) a guide RNA comprising SEQ ID NO:31 and a guide RNA comprising SEQ ID NO:32, (b) a guide RNA comprising SEQ ID NO:33 and a guide RNA comprising SEQ ID NO:34, (c) a guide RNA comprising SEQ ID NO:33 and a guide RNA comprising SEQ ID NO:32, (d) a guide RNA comprising SEQ ID NO:39 and a guide RNA comprising SEQ ID NO:40, (e) a guide RNA comprising SEQ ID NO:41 and a guide RNA comprising SEQ ID NO:42, (f) a guide RNA comprising SEQ ID NO:43 and a guide RNA comprising SEQ ID NO:44, (g) a guide RNA comprising SEQ ID NO:45 and a guide RNA comprising SEQ ID NO:46, (h) a guide RNA comprising SEQ ID NO:47 and a guide RNA comprising SEQ ID NO:48, (i) a guide RNA comprising SEQ ID NO:49 and a guide RNA comprising SEQ ID NO:50, (j) a guide RNA comprising SEQ ID NO:51 and a guide RNA comprising SEQ ID NO:52, (k) a guide RNA comprising SEQ ID NO:53 and a guide RNA comprising SEQ ID NO:54, or (l) a guide RNA comprising SEQ ID NO:55 and a guide RNA comprising SEQ ID NO:56.

### Claim 14 (depends on 1)

The method of claim 1, wherein repair of the double-stranded break by nonhomologous end joining (NHEJ) results in an insertion of at least one nucleotide, a deletion of at least one nucleotide, or a combination thereof, resulting in inactivation of the immune-related genomic locus.

### Claim 15 (depends on 1)

The method of claim 1, wherein the method further comprises introducing into the eukaryotic cell a donor polynucleotide comprising a donor sequence having at least one nucleotide change relative to the immune-related genomic locus, and repair of the double-stranded break by homology-directed repair (HDR) results in integration or exchange of the donor sequence into the immune-related genomic locus, resulting in modification of the immune-related genomic locus.

### Claim 16 (depends on 1)

The method of claim 1, wherein the immune-related genomic locus is selected from 2B4 (CD244), 4-1BB (CD137), A2aR, AAVS1, ACTB, ALB, B2M, B7.1, B7.2, B7-H2, B7-H3, B7-H4, B7-H6, BAFFR, BCL11A, BLAME (SLAMF8), BTLA, butyrophilins, CCR5, CD100 (SEMA4D), CD103, CD11a, CD11b, CD11c, CD11d, CD150, IPO-3), CD160, CD160 (BY55), CD18, CD19, CD2, CD27, CD28, CD29, CD30, CD4, CD40, CD47, CD48, CD49a, CD49D, CD49f, CD52, CD69, CD7, CD83, CD84, CD8alpha, CD8beta, CD96 (Tactile), CDS, CEACAM1, CRTAM, CTLA4, CXCR4, DGK, DGKA, DGKB, DGKD, DGKE, DGKG, DGKI, DGKK, DGKQ, DGKZ, DHFR, DNAM1 (CD226), EP2/4 receptors, adenosine receptors including A2AR, FAS, FASLG, GADS, GITR, GM-CSF, gp49B, HHLA2, HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HIV-LTR (long terminal repeat), HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-I, HVEM, HVEM, IA4, ICAM-1, ICOS, ICOS, ICOS (CD278), IFN-alpha/beta/gamma, IL-1 beta, IL-12, IL-15, IL-18, IL-23, IL2R beta, IL2R gamma, IL2RA, IL-6, IL7R alpha, ILT-2, ILT-4, ITGA4, ITGA4, ITGA6, ITGAD, ITGAE, ITGAL, ITGAM, ITGAX, ITGB1, ITGB2, ITGB7, KIR family receptors, KLRG1, LAIR-1, LAT, LIGHT, LTBR, Ly9 (CD229), MNK1/2, NKG2C, NKG2D, NKp30, NKp44, NKp46, NKp80 (KLRF1), OX2R, OX40, PAG/Cbp, PD-1, PD-L1, PD-L2, PGE2 receptors, PIR-B, PPP1R12C, PSGL1, PTPN2, RANCE/RANKL, ROSA26, SELPLG (CD162), SIRPalpha (CD47), SLAM (SLAMF1, SLAMF4 (CD244, 2B4), SLAMF5, SLAMF6 (NTB-A, Ly108), SLAMF7, SLP-76, TGFBR2, TIGIT, TIM-1, TIM-3, TIM-4, TMIGD2, TRA, TRAC, TRB, TRD, TRG, TNF, TNF-alpha, TNFR2, TUBA1, VISTA, VLA1, and VLA-6.

### Claim 17 (depends on 1)

The method of claim 1, wherein the immune-related genomic locus is selected from Table A:
TABLE A
Target genomic loci
UniProtKB
Gene
Identifier
Protein
Symbol
(human)
Programmed cell death-1 (PD-1)
PD-1
Q15116
Cluster of differentiation 52 (CD52)
CD52
Q9UJ81
Cytotoxic T-lymphocyte protein 4 (CTLA4)
CTLA4
P16410
Lymphocyte-activation protein 3 (LAG3)
LAG3
P18627
Integrin lymphocyte function-associated
ITGAL
P20701
antigen 1 (LFA1) comprising integrin
ITGB2
P05107
alpha L chain (ITGAL) and integrin
beta 2 chain (ITGB2)
Hepatitis A virus cellular receptor 2
HAVCR2
Q8TDQ0
(HAVCR2) (also called T-cell immuno-
globulin and mucin-domain containing-3,
TIM-3)
T-cell receptor alpha constant (TRAC)
TRAC
P01848
T-cell receptor alpha locus (TCR-alpha)
TRA
A0A0C4ZLG8
T-cell receptor beta locus (TCR-beta)
TRB
A0A0C4ZPA0

### Claim 18 (depends on 17)

The method of claim 17, wherein the immune-related genomic locus is PD-1, CTLA4, TIM-3, or TRAC.

### Claim 19

A composition comprising a CRISPR nickase and a pair of guide RNAs engineered to target an immune-related genomic locus.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the CRISPR nickase is a Cas9 nickase, a Cpf1 nickase, or a Cas13a nickase.

### Claim 21 (depends on 20)

The composition of claim 20, wherein the CRISPR nickase is a Cas9 nickase.

### Claim 22 (depends on 21)

The composition of claim 21, wherein the Cas9 nickase is a SpCas9 nickase, a FnCas9 nickase, or a SaCas9 nickase.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the Cas9 nickase is a Cas9-D10A nickase or a Cas9-H840A nickase.

### Claim 24 (depends on 1)

The composition of claim 1, wherein the pair of guide RNAs is chosen from (a) a guide RNA comprising SEQ ID NO:31 and a guide RNA comprising SEQ ID NO:32, (b) a guide RNA comprising SEQ ID NO:33 and a guide RNA comprising SEQ ID NO:34, (c) a guide RNA comprising SEQ ID NO:33 and a guide RNA comprising SEQ ID NO:32, (d) a guide RNA comprising SEQ ID NO:39 and a guide RNA comprising SEQ ID NO:40, (e) a guide RNA comprising SEQ ID NO:41 and a guide RNA comprising SEQ ID NO:42, (f) a guide RNA comprising SEQ ID NO:43 and a guide RNA comprising SEQ ID NO:44, (g) a guide RNA comprising SEQ ID NO:45 and a guide RNA comprising SEQ ID NO:46, (h) a guide RNA comprising SEQ ID NO:47 and a guide RNA comprising SEQ ID NO:48, (i) a guide RNA comprising SEQ ID NO:49 and a guide RNA comprising SEQ ID NO:50, (j) a guide RNA comprising SEQ ID NO:51 and a guide RNA comprising SEQ ID NO:52, (k) a guide RNA comprising SEQ ID NO:53 and a guide RNA comprising SEQ ID NO:54, or (l) a guide RNA comprising SEQ ID NO:55 and a guide RNA comprising SEQ ID NO:56.

### Claim 25 (depends on 1)

A method of treating cancer in a subject, the method comprising modifying an immune-related genomic locus in an ex vivo eukaryotic cell in accordance with claim 1 to prepare a modified eukaryotic cell, and delivering to the subject the modified eukaryotic cell.

### Claim 26 (depends on 25)

The method of claim 25, wherein the eukaryotic cell is a T cell or a population of T cells.
